Domestic tocilizumab manufacturer

Among domestic manufacturers, tocilizumab may be mainly developed and produced by Roche Pharmaceuticals, Beijing Novartis Pharmaceuticals Co., Ltd., and Tianxia Pharmaceuticals. The ingredients and efficacy of the drugs produced by different pharmaceutical companies are basically the same, and there may be differences in prices. Tocilizumab’s original drug has also been launched in China and has entered the scope of medical insurance.

Tocilizumab is a biological agent that is a humanized monoclonal antibody that can bind with the human cytokine interleukin-6 (IL-6), thereby inhibiting its activity. IL-6 is a cytokine that plays an important role in the inflammatory process and is involved in multiple immune and inflammatory responses. It is mainly used to treat rheumatoid arthritis (RA) and other autoimmune diseases, such as childhood idiopathic arthritis, systemic juvenile idiopathic arthritis, etc. It reduces the inflammatory response by inhibiting the IL-6 signaling pathway and improves the symptoms and clinical manifestations of related diseases.

The medical insurance reimbursement conditions of tocilizumaboriginal drug are limited to second-line treatment of systemic juvenile idiopathic arthritis and rheumatoid arthritis patients whose disease activity has decreased by less than 50% after 3-6 months of traditional DMARDs treatment. Tocilizumabinjection can only be used as directed by the doctor. Its price is around 8,600 yuan, which is relatively expensive. The price of the European version of tocilizumab original drug available overseas is around around RMB 14,000 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of the two drugs are basically the same. Currently, there are no generic drugs produced and marketed overseas, and patients can choose by themselves.